These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21252079)

  • 21. Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.
    Renfro LA; Shang H; Sargent DJ
    J Biopharm Stat; 2015; 25(4):857-77. PubMed ID: 24905465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
    Van der Elst W; Molenberghs G; Alonso A
    Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flexible evaluation of surrogacy in platform studies.
    Sachs MC; Gabriel EE; Crippa A; Daniels MJ
    Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On assessing surrogacy in a single trial setting using a semicompeting risks paradigm.
    Ghosh D
    Biometrics; 2009 Jun; 65(2):521-9. PubMed ID: 18759839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
    Cowles MK
    Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
    Brittain EH; Fay MP; Follmann DA
    Biostatistics; 2012 Sep; 13(4):637-49. PubMed ID: 22467938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surrogacy marker paradox measures in meta-analytic settings.
    Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
    Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
    Holzhauer B; Wang C; Schmidli H
    Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian indirect and mixed treatment comparisons across longitudinal time points.
    Ding Y; Fu H
    Stat Med; 2013 Jul; 32(15):2613-28. PubMed ID: 23229717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.
    Dai JY; Hughes JP
    Biostatistics; 2012 Sep; 13(4):609-24. PubMed ID: 22394448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
    Chen N; Lee JJ
    Biom J; 2019 Sep; 61(5):1219-1231. PubMed ID: 30506747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing surrogates as trial endpoints using mixed models.
    Korn EL; Albert PS; McShane LM
    Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian robustness in meta-analysis for studies with zero responses.
    Vázquez FJ; Moreno E; Negrín MA; Martel M
    Pharm Stat; 2016 May; 15(3):230-7. PubMed ID: 26913715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.